April 01, 2016
How to meet the rigorous safety and efficacy demands critical to evaluating newer targeted cancer therapies.
November 25, 2015
As cancer immunotherapies continue to emerge, the need for rigorous evaluation to assess the safety and efficacy of these products in clinical trials is critical. Doing so in the early phase setting requires a foundational focus in such areas as NME selection, protocol development, patient population, and investigator and site selection.